18 November 2026

ECO Animal Health Group plc
(“ECO” or the “Company”)
New marketing authorisations received for Aivlosin®
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces further expansion of Aivlosin®, its market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, with new authorisations in Paraguay and Honduras and import permits providing accelerated routes to markets in Saudi Arabia and Oman.
Commercial sales have already begun in Saudi Arabia and Oman, and will largely leverage the Group’s existing commercial infrastructure for Aivlosin®. Saudi Arabia is a substantial poultry market, growing at 5.8% annually and responsible for over half of the region’s animal health market, providing a meaningful commercial opportunity and is being accessed via a special import license.
David Hallas, Chief Executive Officer of ECO Animal Health, said: “These new marketing authorisations will provide an opportunity for us to expand our market leading Aivlosin® franchise, extending our reach into Latin America and establishing a foothold in a key poultry market in the Middle East. Coupled with recent progress in geographies such as South and South East Asia, these authorisations highlight ECO’s growth potential through our core business in addition to our innovative R&D pipeline.”
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group’s website or LinkedIn page for further information.